Cytosorbents Corp (CTSO) Stock Rating Reaffirmed by Maxim Group
Separately, Brean Capital assumed coverage on shares of Cytosorbents Corp in a research report on Tuesday, October 4th. They set a buy rating and a $24.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, The company presently has an average rating of Buy and an average price target of $14.06.
Shares of Cytosorbents Corp (OTCMKTS:CTSO) opened at 5.95 on Wednesday. The company’s market capitalization is $151.35 million. Cytosorbents Corp has a 12-month low of $3.11 and a 12-month high of $8.10. The company’s 50-day moving average is $5.74 and its 200-day moving average is $4.81.
Cytosorbents Corp (OTCMKTS:CTSO) last released its quarterly earnings data on Tuesday, August 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.03. The firm had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $2.18 million. Analysts predict that Cytosorbents Corp will post ($0.39) EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Advisor Group Inc. acquired a new position in Cytosorbents Corp during the second quarter worth $1,372,000. Raymond James & Associates raised its position in Cytosorbents Corp by 318.6% in the second quarter. Raymond James & Associates now owns 324,603 shares of the company’s stock worth $1,477,000 after buying an additional 247,052 shares during the period. BlackRock Fund Advisors raised its position in Cytosorbents Corp by 39.3% in the second quarter. BlackRock Fund Advisors now owns 53,915 shares of the company’s stock worth $245,000 after buying an additional 15,203 shares during the period. Vanguard Group Inc. raised its position in Cytosorbents Corp by 1.0% in the second quarter. Vanguard Group Inc. now owns 537,707 shares of the company’s stock worth $2,447,000 after buying an additional 5,446 shares during the period. Finally, Douglass Winthrop Advisors LLC acquired a new position in Cytosorbents Corp during the second quarter worth $321,000.
Cytosorbents Corp Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.
Receive News & Ratings for Cytosorbents Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents Corp and related companies with MarketBeat.com's FREE daily email newsletter.